Welcome to our dedicated page for Veru news (Ticker: $VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Veru's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Veru's position in the market.
Veru Inc. reported fiscal 2024 second quarter financial results and provided updates on its Enobosarm high-quality weight loss clinical program. The Phase 2b clinical study of enobosarm in combination with semaglutide is actively enrolling. The company has formed a high-quality weight loss Scientific Advisory Board with five medical experts and will present at upcoming medical conferences. Veru Inc. aims to develop innovative medicines for weight loss, oncology, and respiratory distress syndrome.
Veru Inc. (NASDAQ: VERU) will present at the GLP-1 Based Therapeutics Summit in Philadelphia, discussing Enobosarm, a drug to avoid muscle loss and enhance weight loss quality. The presentation aims to address muscle loss issues in weight management and the potential benefits of combining Enobosarm with a GLP-1 RA. The event is scheduled for May 15-16, 2024.
Veru Inc. (NASDAQ: VERU) will host a conference call and webcast on May 8, 2024, to discuss its fiscal 2024 second quarter financial results and provide a business update. The company focuses on developing innovative medicines for weight loss, oncology, and respiratory distress syndrome.
Veru Inc. (NASDAQ: VERU) has enrolled the first patients in a Phase 2b clinical trial of enobosarm and semaglutide combination for high-quality weight loss. The study aims to preserve muscle mass during weight loss therapy, with topline data expected in the fourth quarter of 2024.